knowledge -WSS

knowledge

author：focus 2025-10-02 18:48:27 - browse：65

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Lilly’s weekly insulin works as well as daily products, new studies show

WSS

Galapagos to make CAR

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Shifting the focus from loneliness to social health

As H5N1 spreads in cows, experts warn against drinking raw milk

ASCO: Palliative care found as helpful given virtually as in person

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

knowledge

knowledge

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Ripples from Flovent's discontinuation is killing children with asthma

New air purifier tech could be key to improving indoor air quality

Galapagos to make CAR

How to save PrEP access — and even expand it

Let's speed up science by embracing open access publishing

In Memoriam: Notable people who died in 2023

Supreme Court to hear if Covid misinformation is protected speech

23andMe had bad news about my health. I wish a person had delivered it

What a koala virus tells us about the human genome

Wikipedia

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Ionis drug prevents swelling attacks due to hereditary angioedema

STAT series 'Denied by AI' wins major journalism prizes

Ionis drug prevents swelling attacks due to hereditary angioedema

Letters to First Opinion on caregivers, digital health, and more

STAT series 'Denied by AI' wins major journalism prizes

leisure time

hotspot

hotspot

explore